Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Advanced Non-Small Cell Lung Cancer Interventions: Drug: GLS-012+GLS-010; Drug: GLS-012+GLS-010+pemetrexed+carboplatin; Drug: GLS-012+GLS-010+paclitaxel+carboplatin Sponsor: Guangzhou Gloria Biosciences Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Retevmo Demonstrates Superior Progression-Free Survival for Adults with Newly-Diagnosed Non-Small Cell Lung Cancer
INDIANAPOLIS, Aug. 4, 2023. Eli Lilly and Company today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed– with or without pembrolizumab– as an initial treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
Conditions: Lung Cancer; Non-small Cell Lung Cancer Interventions: Drug: Lorlatinib; Drug: Cisplatin or Carboplatin; Drug: Pemetrexed Sponsors: SCRI Development Innovations, LLC; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 17, 2023 Category: Research Source Type: clinical trials
